Post-marketing Prospective, Observational Cohort Study to Evaluate the Impact of AbbVie Care Patient Support Program on Compliance With Adalimumab, Patient Reported Outcomes and Health Resource Utilization in Inflammatory Bowel Diseases, Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis and Psoriasis in Portugal
Latest Information Update: 05 Nov 2021
Price :
$35 *
At a glance
- Drugs Adalimumab (Primary)
- Indications Ankylosing spondylitis; Crohn's disease; Inflammatory bowel diseases; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
- Focus Therapeutic Use
- Acronyms IMPROVE
- Sponsors AbbVie
- 15 Feb 2019 Status changed from active, no longer recruiting to completed.
- 21 Dec 2018 Planned End Date changed from 30 Nov 2019 to 30 Apr 2019.
- 21 Dec 2018 Planned primary completion date changed from 30 Nov 2019 to 30 Apr 2019.